Covid-19, H1N1 influenza, SARS-COV-1, Dengue, Zika, Ebola…: Eukarÿs announces the SHIELD evaluation study for Synthetic Gene Vaccination

March 30, 2020

Covid-19: Eukarÿs makes its C3P3 system available to the scientific community to accelerate the fight against SARS-CoV-2

March 28, 2020

Eukarÿs semi-finalist of the Merck-Millipore’s European Advance Biotech Competition

March 14, 2020

Guillaume Prunier appointed Special Advisor to the President

March 12, 2020

Eukarÿs is nominated at the EIT Health Summit 2019

November 29, 2019

EUK-LPR: Eukarÿs confirms excellent preclinical performance of its first synthetic gene therapy

November 14, 2019

Eukarÿs wins the Galien MedStartUp 2019 Award

October 29, 2019

Galien MedStartup Award: Eukarÿs nominated among the three finalists

October 18, 2019

According to the Journal Insightscare, Eukarÿs is one of The 10 Most Innovative Companies In Gene Therapy

September 09, 2019

Eukarÿs to showcase C3P3 technology and bioproduction applications at PEGS Europe Conference

June 24, 2019

Eukarÿs reaches the final of the RESI Innovation Challenge 2019

March 3, 2019

Eukarÿs publishes the construction process of C3P3-G1, the prototype of the C3P3 artificial expression system

February 6, 2019

Eukarÿs announces the finalization of the 3rd generation of its C3P3 expression system

January 15, 2019

Eukarÿs SAS and PPRS Research Announce Capital and Strategic Partnership

November 21, 2018